What changed in Regeneron Pharmaceuticals, Inc.'s latest annual report
In the year ended 31 Dec 2025, Regeneron Pharmaceuticals, Inc.'s revenue rose 1% to USD 14.34bn, from USD 14.20bn; net income rose 2.1% to USD 4.50bn, from USD 4.41bn; cash and cash equivalents rose 25.3% to USD 3.12bn, from USD 2.49bn.
Year ended 31 Dec 2025. Source: 10-K filed 4 Feb 2026, read it on SEC EDGAR.
USD 14.20bn to USD 14.34bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 14.20bn | 14.34bn | Up 1% |
| Net income | 4.41bn | 4.50bn | Up 2.1% |
| Total assets | 37.76bn | 40.56bn | Up 7.4% |
| Total liabilities | 8.41bn | 9.30bn | Up 10.7% |
| Long-term debt | 1.98bn | 1.99bn | Up 0.1% |
| Cash and cash equivalents | 2.49bn | 3.12bn | Up 25.3% |
| Shareholders' equity | 29.35bn | 31.26bn | Up 6.5% |
Questions people ask
Did Regeneron Pharmaceuticals, Inc.'s revenue grow last year?
Revenue grew 1%, from USD 14.20bn to USD 14.34bn in the year ended 31 Dec 2025.
Is Regeneron Pharmaceuticals, Inc. profitable?
Yes. Net income was USD 4.50bn in the year ended 31 Dec 2025. The year before: USD 4.41bn.
How much cash and debt does Regeneron Pharmaceuticals, Inc. have?
At its latest year end (31 Dec 2025), Regeneron Pharmaceuticals, Inc. reported cash and cash equivalents of USD 3.12bn and long-term debt of USD 1.99bn.
Where do these numbers come from?
From Regeneron Pharmaceuticals, Inc.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Regeneron Pharmaceuticals, Inc.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%